Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Sinovac Biotech Ltd (SVA), a leading provider of biopharmaceutical products in China, announced a new partnership into a collaboration to develop a vaccine to prevent COVID-19. The collaboration will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate with Dynavax’s advanced adjuvant, CpG 1018.
What is CpG 1018?
An adjuvant used in HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA). Dynavax developed CpG 1018 to offer an increased vaccine immune response, which has been demonstrated in HEPLISAV-B. CpG 1018 provides a well-developed technology and a significant safety database, potentially accelerating the development of a coronavirus vaccine. The product is manufactured using a highly automated, robust, scalable process capable of producing the large quantities required in a pandemic reports the company in a press release.
Other COVID-19 Activity
With a global COVID-19 pandemic unfolding, Dynavax has inked deals with the Coalition for Epidemic Preparedness Innovation and Clover Pharmaceuticals in bids to contribute to vaccine development. These other partnerships involve CpG 1018 as an adjuvant to boost patients’ immune response to vaccines.
Founded in 1996 and based in Emeryville, CA, Dynavax has been a commercial stage biotechnology company developing and commercializing novel vaccines. The company launched HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted],its first commercial product, in February 2018 following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adult age 18 years and older.
The company’s stock DVX trades at $3.53 per share; its stock price has been depressed for a long time. The company presently operates at a projected loss of $103 million.